In the management of PCA, PSMA has already become an attractive target for oncological imaging and radionuclide therapy since its expression persisted in a high percentage of these patients, confirmed by positron emission tomography/computer tomography (58). This evidence concerns the gene FOLH1 and posterior cortical atrophy.